- Home
- NBR vs REPL Comparison
NBR vs REPL Comparison
Compare NBR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- REPL
- Stock Information
- Founded
- NBR 1952
- REPL 2015
- Country
- NBR Bermuda
- REPL United States
- Employees
- NBR N/A
- REPL N/A
- Industry
- NBR Oil & Gas Production
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- REPL Health Care
- Exchange
- NBR Nasdaq
- REPL Nasdaq
- Market Cap
- NBR 529.5M
- REPL 547.0M
- IPO Year
- NBR N/A
- REPL 2018
- Fundamental
- Price
- NBR $36.81
- REPL $5.40
- Analyst Decision
- NBR Hold
- REPL Buy
- Analyst Count
- NBR 8
- REPL 10
- Target Price
- NBR $45.63
- REPL $8.25
- AVG Volume (30 Days)
- NBR 558.0K
- REPL 4.6M
- Earning Date
- NBR 10-21-2025
- REPL 08-07-2025
- Dividend Yield
- NBR N/A
- REPL N/A
- EPS Growth
- NBR N/A
- REPL N/A
- EPS
- NBR N/A
- REPL N/A
- Revenue
- NBR $3,030,598,000.00
- REPL N/A
- Revenue This Year
- NBR $11.94
- REPL N/A
- Revenue Next Year
- NBR $2.68
- REPL $408.25
- P/E Ratio
- NBR N/A
- REPL N/A
- Revenue Growth
- NBR 3.49
- REPL N/A
- 52 Week Low
- NBR $23.27
- REPL $2.68
- 52 Week High
- NBR $86.10
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- NBR 57.57
- REPL 44.04
- Support Level
- NBR $34.40
- REPL $5.08
- Resistance Level
- NBR $36.75
- REPL $5.91
- Average True Range (ATR)
- NBR 2.14
- REPL 0.33
- MACD
- NBR 0.22
- REPL 0.15
- Stochastic Oscillator
- NBR 89.29
- REPL 46.88
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.